BioNexus Gene Lab (BGLC) Shares Outstanding (Weighted Average) (2018 - 2026)

BioNexus Gene Lab has disclosed Shares Outstanding (Weighted Average) across 9 years of filings, most recently posting $2.4 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $2.4 million, up 34.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.4 million (up 34.54% YoY), and the FY2025 annual result was $1.9 million, up 4.2% from the prior year.
• Shares Outstanding (Weighted Average) came in at $2.4 million for Q1 2026 at BioNexus Gene Lab, up from $1.9 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $172.1 million in Q2 2022 to a low of $1.8 million in Q4 2024.
• The 5-year median for Shares Outstanding (Weighted Average) is $14.5 million (2023), against an average of $29.3 million.
• Across the five-year window, Shares Outstanding (Weighted Average) sank 91.59% in 2023 and jumped 34.54% in 2026, its largest moves.
• BioNexus Gene Lab's Shares Outstanding (Weighted Average) stood at $14.4 million in 2022, then climbed by 10.17% to $15.9 million in 2023, then tumbled by 88.78% to $1.8 million in 2024, then rose by 4.2% to $1.9 million in 2025, then surged by 30.2% to $2.4 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $2.4 million (Q1 2026), $1.9 million (Q4 2025), and $1.8 million (Q3 2025), per Business Quant data.